Differential Genomic and Proteomic Signatures In Cord Blood (CB) Vs Peripheral Blood (PB) CD56+Dim NK Cells: Over Expression of CD34 In CB Vs PB CD56+Dim NK Cells
Abstract 2781 Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both malignant and non-malignant disease (Cairo et al BBMT 2008). UCB transplantation (UCBT) is known to be associated with decrease severe acute graft-versus-host dise...
Saved in:
Published in | Blood Vol. 116; no. 21; p. 2781 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
19.11.2010
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract 2781
Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both malignant and non-malignant disease (Cairo et al BBMT 2008). UCB transplantation (UCBT) is known to be associated with decrease severe acute graft-versus-host disease (GvHD) compared to unrelated bone marrow (BM) and peripheral blood (PB) transplantation; however, it is associated with delayed hematopoietic and immune reconstitution (Szabolcs/Cairo et al Seminars in Hematology 2010). NK cells play important roles in both innate and adaptive immunity and are characterized as a CD56+ cell population. NK cell recovery is prompt by 2 months after hematopoietic stem cell transplantation (HSCT), while T-cell (after at least 9 mo HSCT) and B-cell (after 3 to 4 mo HSCT) reconstitutions are gradual and delayed. CD56+dim cells are primarily cytotoxic and make up 90% of PB NK populations (Shereck/Cairo PBC 2007). We previously demonstrated the ability to ex-vivo expand CB MNC into various phenotypes of CD56+dim and CD56+bright NK cells (totally 60%) and NKT cells (40%) with profound in vitro and in vivo cytotoxicity against hematological malignancies (Ayello/Cairo BBMT 2006 & Exp. Hematology 2009). Proteomic studies from our group demonstrated differential protein expression including ↑NKG2A, ↓IP3R type 3, ↓MAPKAPK5, and ↑NOTCH 2 in CB vs PB CD56+dim (Shereck/Cairo, ASH 2007; Shereck/Day/Cairo, ASBMT 2009).
In these studies, we sought to determine the similarity or differences in genetic signatures in CB vs APB CD56+dim NK cells.
CB MNCs were isolated on a ficoll gradient and NK CD56+16+dim cells isolated using a 2-step magnetic activated cell separation (MACS) process via a standard kit (Miltenyi Biotec). Enrichment was at least 94%. Isolated RNA from CB and PB CD56+dim cells were subjected to microarray studies (Affymetrix, U133A_2) as we have previously described (Jiang/Cairo et al J Immunol 2004). Data were analyzed by Agilent GeneSpring and Ingenuity pathway analyses. Welch test were used to perform statistical analysis and fold change of < 1.5 and values of p<0.05 were considered to be significant. Two-color ECL Plex fluorescence Western blotting (WB) was preformed to validate the proteomic data. Protein samples were separated using SDS-PAGE followed by transblotting. WB membranes were then incubated with target and control (GAPDH) primary antibodies. After rinse and wash, the membranes were further incubated with CY5 and CY3 conjugated secondary antibodies. The membranes were scanned with TYPHOON by green (532 laser and 580 filter) and red (633 laser and 670 filter) setting for CY3 and CY5, respectively, and then observed and quantified using ImageQuant.
CB vs PB CD56+dim cells significantly altered expressed 796 genes, in which 486 genes were over expressed, at the genomic level including: pro-apoptotic genes: CASP10 (3.1F), TNFSF11 (4.7F), CDC2 (3.0F), BCL2L1 (4.3F), NOTCH2 (1.5F); and cell development: PBX1 (7.6F), IL1RN (5.1F), CD24 (5.3F), CD34 (3.5F), CD55 (2.1F), CCL13 (2.2F). Conversely, there was significant under expression of NF1 (5.1F), MAP2K3 (1.7F), PIK3CD (2.1F), BAX (2.9F), and JUN (2.2F). Our WB results indicate that NOTCH2 (2.4F) and PBX1 (2.2F) proteins are increased in CB vs PB CD56+dim NK cells, consistent with our proteomic results.
These results suggest that CB vs PB CD56+dim NK are more prone to undergo programmed cell death (apoptosis) secondary to over expression of numerous pro-apoptotic genes, and may be earlier in development (pro-NK) with over expression of the CD34 gene. Furthermore, decrease CB vs PB NK cytotoxicity maybe in part secondary to increase programmed cell death in particularly increase NOTCH2 at the genomic and proteomic levels. (The first two authors contribute equally.)
No relevant conflicts of interest to declare. |
---|---|
AbstractList | Abstract 2781
Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both malignant and non-malignant disease (Cairo et al BBMT 2008). UCB transplantation (UCBT) is known to be associated with decrease severe acute graft-versus-host disease (GvHD) compared to unrelated bone marrow (BM) and peripheral blood (PB) transplantation; however, it is associated with delayed hematopoietic and immune reconstitution (Szabolcs/Cairo et al Seminars in Hematology 2010). NK cells play important roles in both innate and adaptive immunity and are characterized as a CD56+ cell population. NK cell recovery is prompt by 2 months after hematopoietic stem cell transplantation (HSCT), while T-cell (after at least 9 mo HSCT) and B-cell (after 3 to 4 mo HSCT) reconstitutions are gradual and delayed. CD56+dim cells are primarily cytotoxic and make up 90% of PB NK populations (Shereck/Cairo PBC 2007). We previously demonstrated the ability to ex-vivo expand CB MNC into various phenotypes of CD56+dim and CD56+bright NK cells (totally 60%) and NKT cells (40%) with profound in vitro and in vivo cytotoxicity against hematological malignancies (Ayello/Cairo BBMT 2006 & Exp. Hematology 2009). Proteomic studies from our group demonstrated differential protein expression including ↑NKG2A, ↓IP3R type 3, ↓MAPKAPK5, and ↑NOTCH 2 in CB vs PB CD56+dim (Shereck/Cairo, ASH 2007; Shereck/Day/Cairo, ASBMT 2009).
In these studies, we sought to determine the similarity or differences in genetic signatures in CB vs APB CD56+dim NK cells.
CB MNCs were isolated on a ficoll gradient and NK CD56+16+dim cells isolated using a 2-step magnetic activated cell separation (MACS) process via a standard kit (Miltenyi Biotec). Enrichment was at least 94%. Isolated RNA from CB and PB CD56+dim cells were subjected to microarray studies (Affymetrix, U133A_2) as we have previously described (Jiang/Cairo et al J Immunol 2004). Data were analyzed by Agilent GeneSpring and Ingenuity pathway analyses. Welch test were used to perform statistical analysis and fold change of < 1.5 and values of p<0.05 were considered to be significant. Two-color ECL Plex fluorescence Western blotting (WB) was preformed to validate the proteomic data. Protein samples were separated using SDS-PAGE followed by transblotting. WB membranes were then incubated with target and control (GAPDH) primary antibodies. After rinse and wash, the membranes were further incubated with CY5 and CY3 conjugated secondary antibodies. The membranes were scanned with TYPHOON by green (532 laser and 580 filter) and red (633 laser and 670 filter) setting for CY3 and CY5, respectively, and then observed and quantified using ImageQuant.
CB vs PB CD56+dim cells significantly altered expressed 796 genes, in which 486 genes were over expressed, at the genomic level including: pro-apoptotic genes: CASP10 (3.1F), TNFSF11 (4.7F), CDC2 (3.0F), BCL2L1 (4.3F), NOTCH2 (1.5F); and cell development: PBX1 (7.6F), IL1RN (5.1F), CD24 (5.3F), CD34 (3.5F), CD55 (2.1F), CCL13 (2.2F). Conversely, there was significant under expression of NF1 (5.1F), MAP2K3 (1.7F), PIK3CD (2.1F), BAX (2.9F), and JUN (2.2F). Our WB results indicate that NOTCH2 (2.4F) and PBX1 (2.2F) proteins are increased in CB vs PB CD56+dim NK cells, consistent with our proteomic results.
These results suggest that CB vs PB CD56+dim NK are more prone to undergo programmed cell death (apoptosis) secondary to over expression of numerous pro-apoptotic genes, and may be earlier in development (pro-NK) with over expression of the CD34 gene. Furthermore, decrease CB vs PB NK cytotoxicity maybe in part secondary to increase programmed cell death in particularly increase NOTCH2 at the genomic and proteomic levels. (The first two authors contribute equally.)
No relevant conflicts of interest to declare. Abstract Abstract 2781 Background. Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both malignant and non-malignant disease (Cairo et al BBMT 2008). UCB transplantation (UCBT) is known to be associated with decrease severe acute graft-versus-host disease (GvHD) compared to unrelated bone marrow (BM) and peripheral blood (PB) transplantation; however, it is associated with delayed hematopoietic and immune reconstitution (Szabolcs/Cairo et al Seminars in Hematology 2010). NK cells play important roles in both innate and adaptive immunity and are characterized as a CD56+ cell population. NK cell recovery is prompt by 2 months after hematopoietic stem cell transplantation (HSCT), while T-cell (after at least 9 mo HSCT) and B-cell (after 3 to 4 mo HSCT) reconstitutions are gradual and delayed. CD56+dim cells are primarily cytotoxic and make up 90% of PB NK populations (Shereck/Cairo PBC 2007). We previously demonstrated the ability to ex-vivo expand CB MNC into various phenotypes of CD56+dim and CD56+bright NK cells (totally 60%) and NKT cells (40%) with profound in vitro and in vivo cytotoxicity against hematological malignancies (Ayello/Cairo BBMT 2006 & Exp. Hematology 2009). Proteomic studies from our group demonstrated differential protein expression including ↑NKG2A, ↓IP3R type 3, ↓MAPKAPK5, and ↑NOTCH 2 in CB vs PB CD56+dim (Shereck/Cairo, ASH 2007; Shereck/Day/Cairo, ASBMT 2009). Objective. In these studies, we sought to determine the similarity or differences in genetic signatures in CB vs APB CD56+dim NK cells. Methods. CB MNCs were isolated on a ficoll gradient and NK CD56+16+dim cells isolated using a 2-step magnetic activated cell separation (MACS) process via a standard kit (Miltenyi Biotec). Enrichment was at least 94%. Isolated RNA from CB and PB CD56+dim cells were subjected to microarray studies (Affymetrix, U133A_2) as we have previously described (Jiang/Cairo et al J Immunol 2004). Data were analyzed by Agilent GeneSpring and Ingenuity pathway analyses. Welch test were used to perform statistical analysis and fold change of < 1.5 and values of p<0.05 were considered to be significant. Two-color ECL Plex fluorescence Western blotting (WB) was preformed to validate the proteomic data. Protein samples were separated using SDS-PAGE followed by transblotting. WB membranes were then incubated with target and control (GAPDH) primary antibodies. After rinse and wash, the membranes were further incubated with CY5 and CY3 conjugated secondary antibodies. The membranes were scanned with TYPHOON by green (532 laser and 580 filter) and red (633 laser and 670 filter) setting for CY3 and CY5, respectively, and then observed and quantified using ImageQuant. Results. CB vs PB CD56+dim cells significantly altered expressed 796 genes, in which 486 genes were over expressed, at the genomic level including: pro-apoptotic genes: CASP10 (3.1F), TNFSF11 (4.7F), CDC2 (3.0F), BCL2L1 (4.3F), NOTCH2 (1.5F); and cell development: PBX1 (7.6F), IL1RN (5.1F), CD24 (5.3F), CD34 (3.5F), CD55 (2.1F), CCL13 (2.2F). Conversely, there was significant under expression of NF1 (5.1F), MAP2K3 (1.7F), PIK3CD (2.1F), BAX (2.9F), and JUN (2.2F). Our WB results indicate that NOTCH2 (2.4F) and PBX1 (2.2F) proteins are increased in CB vs PB CD56+dim NK cells, consistent with our proteomic results. Conclusion. These results suggest that CB vs PB CD56+dim NK are more prone to undergo programmed cell death (apoptosis) secondary to over expression of numerous pro-apoptotic genes, and may be earlier in development (pro-NK) with over expression of the CD34 gene. Furthermore, decrease CB vs PB NK cytotoxicity maybe in part secondary to increase programmed cell death in particularly increase NOTCH2 at the genomic and proteomic levels. (The first two authors contribute equally.) Disclosures: No relevant conflicts of interest to declare. |
Author | Shereck, Evan Ayello, Janet van de Ven, Carmella Wapner, Ronald J McGuinn, Catherine Atallah, Juliana Cairo, Mitchell S. Day, Nancy S Satwani, Prakash Lim, Megan S. |
Author_xml | – sequence: 1 givenname: Nancy S surname: Day fullname: Day, Nancy S organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA – sequence: 2 givenname: Evan surname: Shereck fullname: Shereck, Evan organization: Pediatric Oncology/Hematology, British Columbia Children's Hospital, Vancouver, BC, Canada – sequence: 3 givenname: Janet surname: Ayello fullname: Ayello, Janet organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA – sequence: 4 givenname: Catherine surname: McGuinn fullname: McGuinn, Catherine organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA – sequence: 5 givenname: Prakash surname: Satwani fullname: Satwani, Prakash organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA – sequence: 6 givenname: Juliana surname: Atallah fullname: Atallah, Juliana organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA – sequence: 7 givenname: Carmella surname: van de Ven fullname: van de Ven, Carmella organization: Pediatrics, Columbia University, NewYork-Presbyterian, Morgan Stanley Children's Hospital, New York, NY, USA – sequence: 8 givenname: Ronald J surname: Wapner fullname: Wapner, Ronald J organization: Obstetrics/Gynecology, Morgan Stanley Children's Hospital of New-York Presbyterian, Columbia University, New York, NY, USA – sequence: 9 givenname: Megan S. surname: Lim fullname: Lim, Megan S. organization: Department of Pathology, The University of Michigan, Ann Arbor, MI, USA – sequence: 10 givenname: Mitchell S. surname: Cairo fullname: Cairo, Mitchell S. organization: Pediatrics, Medicine, Pathology and Cell Biology, Columbia University, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA |
BookMark | eNqFkMtOwzAQRS1UJMrjG_AShBJsx3mUHU2hVCCoxGNrJfYYjFK7skMFv8OXkqTsWLCYO7LG94x999HIOgsIHVMSU1qw87pxTsUvlGYxozHLi63soDFNWRERwsgIjQkhWcQnOd1D-yG8E0J5wtIx-p4ZrcGDbU3V4DlYtzISV1bhpXctDKdH82qr9sNDwAuLS-cVnvZL8Uk5PcUvAS_Bm_Ub-I7wO1h2g3KWZmczs8L3t7iEpgkX-GEDHl99rjtUMM5ip7tbCR-w04E0_Ws7RLu6agIc_fYD9Hx99VTeRHcP80V5eRdJSjIa6UqrjCU643WqKOhcS0KriQbZF4ckqdMir0lRpFmueMWV7H5OUsYk52mhkgOUb7nSuxA8aLH2ZlX5L0GJ6KMWQ9Sij1owKvqUB-mcl1sndM_bGPAiSANWgjIeZCuUM_8yfgDC6Ihl |
ContentType | Journal Article |
Copyright | 2010 American Society of Hematology |
Copyright_xml | – notice: 2010 American Society of Hematology |
DBID | 6I. AAFTH AAYXX CITATION |
DOI | 10.1182/blood.V116.21.2781.2781 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 2781 |
ExternalDocumentID | 10_1182_blood_V116_21_2781_2781 S0006497119448489 |
GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 9M8 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFFNX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N4W N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ 0SF AALRI AAYXX ADVLN AITUG AKRWK AMRAJ CITATION H13 |
ID | FETCH-LOGICAL-c1061-fafd623f64b5d1ef7fc01a9fec9fec4e33b587b088567d4a4dcffe0522c4458d3 |
IEDL.DBID | ABVKL |
ISSN | 0006-4971 |
IngestDate | Fri Aug 23 00:28:05 EDT 2024 Fri Feb 23 02:43:41 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 21 |
Language | English |
License | This article is made available under the Elsevier license. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1061-fafd623f64b5d1ef7fc01a9fec9fec4e33b587b088567d4a4dcffe0522c4458d3 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0006497119448489 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1182_blood_V116_21_2781_2781 elsevier_sciencedirect_doi_10_1182_blood_V116_21_2781_2781 |
PublicationCentury | 2000 |
PublicationDate | 2010-11-19 |
PublicationDateYYYYMMDD | 2010-11-19 |
PublicationDate_xml | – month: 11 year: 2010 text: 2010-11-19 day: 19 |
PublicationDecade | 2010 |
PublicationTitle | Blood |
PublicationYear | 2010 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0014325 |
Score | 2.0280063 |
Snippet | Abstract 2781
Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both malignant and... Abstract Abstract 2781 Background. Umbilical cord blood (UCB) is a viable alternative source of allogeneic hematopoietic stem cells for the treatment of both... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 2781 |
Title | Differential Genomic and Proteomic Signatures In Cord Blood (CB) Vs Peripheral Blood (PB) CD56+Dim NK Cells: Over Expression of CD34 In CB Vs PB CD56+Dim NK Cells |
URI | https://dx.doi.org/10.1182/blood.V116.21.2781.2781 |
Volume | 116 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LbtQwcNRuxeNSwRZEoa18QAgO6a5jO7Z726QthaVlEXTVW5Q4Nlppm1ZskeB3-NKOHQeBQOLAIVYSZ6w4M55HPA-A5y7VyPYbm2TG6oQ7LRKVKZZoVjVoNdeOGR_gfHqWnZzztxfiYg2KPhbGu1VG3t_x9MCt451R_Jqj68XCx_iiONWSohnOFVd6HTZSmY3TAWxM8vn03c_NBM7SrpABGs8eILp5oWY9Ct7h-3NKs_0UrUWpuubvQuoXwXP8ADajxkgm3Us9hDXbDmFr0qK1fPmdvCDBhzP8HB_Cnbw_u1f0ldyGcPc0bqBvwY_DWBAFF_aSvLYhKJlUbUNmPmFDuPq4-Nyl-1yRNy0p0DoluZ8AeVnkr8h8RWZItSEbwbLvmGFHcSiQiBaX5GxKCrtcrg7Ie1wn5Ohb9LVtyZXDpxgPw-ZhpPxPsEdwfnz0qThJYpmGxHh7MnGVa1CJchmvRUOtk86MaaWdNf7glrFaKFkjOxOZbHjFG4MzHaPiZzgXqmGPYdBetfYJEEVdTaUyda0oN1LoTDruqJCsckIbvg3jHi_ldZeNowxWjErLgMrSo7JMaemxGJptOOjxV_5GWCXKjH8BP_0f4GdwP7gaeJ9BvQODmy9f7S5qMDf1XqTQPVifflC3oDDphQ |
link.rule.ids | 315,786,790,27602,27957,27958,45698 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LbtQwcFS2gvaCYAui5eUDQnBId53Ysd3bJm3Zsg9Wol31FiWOjVbaphVbJPgdvpSx4yAQSBw4xErijBVnxvOI5wHwysYK2X5tolQbFTGreCRTmUQqKWu0miubaBfgPJun4wv2_pJfbkHexcI4t8rA-1ue7rl1uDMIX3Nws1q5GF8Up0pQNMOZZFLdgW3UBpTswfYoW06mPzcTWBK3hQzQeHYAwc0LNeuB9w4_XFKaHsZoLQrZNn8XUr8IntMHcD9ojGTUvtRD2DJNH_ZGDVrLV9_Ia-J9OP3P8T7czbqznbyr5NaHe7Owgb4H349DQRRc2GvyzvigZFI2NVm4hA3-6uPqU5vuc0POGpKjdUoyNwHyJs_ekuWGLJBqfTaCddexwI78mCMRra7IfEJys15vjsgHXCfk5GvwtW3ItcWnEuaHzfxI2Z9gj-Di9OQ8H0ehTEOknT0Z2dLWqETZlFW8psYKq4e0VNZodzCTJBWXokJ2xlNRs5LVGmc6RMVPM8ZlnTyGXnPdmCdAJLUVFVJXlaRMC65SYZmlXCSl5UqzfRh2eClu2mwchbdiZFx4VBYOlUVMC4dF3-zDUYe_4jfCKlBm_Av44H-AX8LO-Hw2LaZn88lT2PVuB85_UD2D3u3nL-Y5ajO31YtArT8AWd3riQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+Genomic+and+Proteomic+Signatures+In+Cord+Blood+%28CB%29+Vs+Peripheral+Blood+%28PB%29+CD56%2BDim+NK+Cells%3A+Over+Expression+of+CD34+In+CB+Vs+PB+CD56%2BDim+NK+Cells&rft.jtitle=Blood&rft.au=Day%2C+Nancy+S&rft.au=Shereck%2C+Evan&rft.au=Ayello%2C+Janet&rft.au=McGuinn%2C+Catherine&rft.date=2010-11-19&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=116&rft.issue=21&rft.spage=2781&rft.epage=2781&rft_id=info:doi/10.1182%2Fblood.V116.21.2781.2781&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_V116_21_2781_2781 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |